Documenti analoghi

• Editorial: Comparable Hepatic Fibrosis Risk Demands Equal Vigilance in Lean and Non‐Lean Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease—Authors' Reply
  di: Kaleb Tesfai, et al.
  Pubblicazione: (2025)
• Editorial: Steatotic Liver Diseases Emerge as Rapidly Growing Drivers of Primary Liver Cancer in the United States
  di: Kelly Torosian, et al.
  Pubblicazione: (2025)
• Editorial: Genetics for non‐invasive risk stratification—Finding the needle in the haystack? Authors' reply
  di: Lana Bridi, et al.
  Pubblicazione: (2024)
• Editorial: Comparable Hepatic Fibrosis Risk Demands Equal Vigilance in Lean and Non‐Lean Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease
  di: Shinya Yokoyama, et al.
  Pubblicazione: (2025)
• Editorial: Does Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD ) With Advanced Fibrosis Also Equate to Risk of Advanced Coronary Artery Disease?
  di: C. C. Mark Cheah, et al.
  Pubblicazione: (2025)